SG11201502372SA - Recombinant clostridium botulinum neurotoxins - Google Patents
Recombinant clostridium botulinum neurotoxinsInfo
- Publication number
- SG11201502372SA SG11201502372SA SG11201502372SA SG11201502372SA SG11201502372SA SG 11201502372S A SG11201502372S A SG 11201502372SA SG 11201502372S A SG11201502372S A SG 11201502372SA SG 11201502372S A SG11201502372S A SG 11201502372SA SG 11201502372S A SG11201502372S A SG 11201502372SA
- Authority
- SG
- Singapore
- Prior art keywords
- clostridium botulinum
- botulinum neurotoxins
- recombinant clostridium
- recombinant
- neurotoxins
- Prior art date
Links
- 108030001720 Bontoxilysin Proteins 0.000 title 1
- 241000193155 Clostridium botulinum Species 0.000 title 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201219602A GB201219602D0 (en) | 2012-10-31 | 2012-10-31 | Recombinant clostridium botulinum neurotoxins |
| PCT/GB2013/052845 WO2014068317A1 (en) | 2012-10-31 | 2013-10-31 | Recombinant clostridium botulinum neurotoxins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201502372SA true SG11201502372SA (en) | 2015-05-28 |
Family
ID=47358958
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201502372SA SG11201502372SA (en) | 2012-10-31 | 2013-10-31 | Recombinant clostridium botulinum neurotoxins |
| SG10201701140WA SG10201701140WA (en) | 2012-10-31 | 2013-10-31 | Recombinant clostridium botulinum neurotoxins |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201701140WA SG10201701140WA (en) | 2012-10-31 | 2013-10-31 | Recombinant clostridium botulinum neurotoxins |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10030238B2 (enExample) |
| EP (3) | EP3326644B1 (enExample) |
| JP (2) | JP2019068823A (enExample) |
| KR (2) | KR102264478B1 (enExample) |
| CN (2) | CN104755098A (enExample) |
| AR (2) | AR093309A1 (enExample) |
| AU (3) | AU2013340610B2 (enExample) |
| BR (1) | BR112015005384A2 (enExample) |
| CA (1) | CA2885519A1 (enExample) |
| DK (2) | DK2914282T3 (enExample) |
| EA (1) | EA201590794A8 (enExample) |
| ES (2) | ES2662402T3 (enExample) |
| GB (1) | GB201219602D0 (enExample) |
| HU (2) | HUE048802T2 (enExample) |
| IL (1) | IL237623B (enExample) |
| IN (1) | IN2015MN00436A (enExample) |
| MX (2) | MX367080B (enExample) |
| NO (1) | NO2914282T3 (enExample) |
| NZ (1) | NZ705575A (enExample) |
| PL (2) | PL2914282T3 (enExample) |
| PT (2) | PT3326644T (enExample) |
| SG (2) | SG11201502372SA (enExample) |
| TW (3) | TWI673361B (enExample) |
| UA (1) | UA118837C2 (enExample) |
| WO (1) | WO2014068317A1 (enExample) |
| ZA (1) | ZA201501449B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201219602D0 (en) * | 2012-10-31 | 2012-12-12 | Syntaxin Ltd | Recombinant clostridium botulinum neurotoxins |
| RU2746736C2 (ru) | 2015-03-26 | 2021-04-20 | Президент Энд Феллоуз Оф Гарвард Колледж | Сконструированный ботулинический нейротоксин |
| WO2017063743A1 (en) | 2015-10-14 | 2017-04-20 | Merz Pharma Gmbh & Co. Kgaa | Improvements to ultrasound-based therapy of photoaged tissue |
| MX395130B (es) | 2016-03-02 | 2025-03-24 | Merz Pharma Gmbh & Co Kgaa | Composicion que comprende toxina botulinica |
| EP3263710A1 (en) * | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
| EP3504226A1 (en) | 2016-08-24 | 2019-07-03 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
| JP7217700B2 (ja) | 2016-09-13 | 2023-02-03 | アラーガン、インコーポレイテッド | 安定化非タンパク質クロストリジウム毒素組成物 |
| EP3642222A1 (en) | 2017-06-20 | 2020-04-29 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum toxin with increased duration of effect |
| US11155802B2 (en) | 2017-07-06 | 2021-10-26 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum neurotoxins with increased duration of effect |
| CA3078631A1 (en) | 2017-10-11 | 2019-04-18 | Jacob M. Waugh | Methods and compositions for topical delivery |
| BR112020006827A2 (pt) * | 2018-01-29 | 2020-10-06 | Ipsen Biopharm Limited | neurotoxinas botulínicas clivando snare não neuronal |
| US11707510B2 (en) * | 2018-02-16 | 2023-07-25 | Preclinics Discovery Gmbh | Nucleic acid-based botulinum neurotoxin for therapeutic use |
| GB201815844D0 (en) * | 2018-09-28 | 2018-11-14 | Ipsen Biopharm Ltd | Therapeutic & comestic uses of botulinum neurotoxin serotype e |
| GB202011055D0 (en) | 2020-07-17 | 2020-09-02 | Ipsen Bioinnovation Ltd | Treatment of post-operative pain |
| GB202015618D0 (en) | 2020-10-01 | 2020-11-18 | Ipsen Biopharm Ltd | Method for producing beta-trypsin |
| CN115819526A (zh) * | 2022-12-02 | 2023-03-21 | 海雅美生物技术(珠海)有限公司 | 一种重组肉毒杆菌神经毒素及其制备方法和应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6967088B1 (en) | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
| NZ308772A (en) * | 1995-05-17 | 1999-04-29 | Du Pont | Recombinant baculovirus insecticides |
| WO2000002524A2 (en) | 1998-07-10 | 2000-01-20 | U.S. Army Medical Research Institute Of Infectious Diseases | Botulinum neurotoxin vaccine |
| EP2267008B1 (en) | 1999-08-25 | 2014-07-02 | Allergan, Inc. | Activatable recombinant neurotoxins |
| US7374896B2 (en) | 2001-08-28 | 2008-05-20 | Allergan, Inc. | GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity |
| US7825233B2 (en) * | 2004-06-30 | 2010-11-02 | Allergan, Inc. | Optimizing expression of active Botulinum Toxin type E |
| US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| US20110111483A1 (en) * | 2004-06-30 | 2011-05-12 | Allergan, Inc. | Optimizing Expression of Active Botulinum Toxin Type E |
| GB2416122A (en) * | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
| DE102004043009A1 (de) * | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| DE102005002978B4 (de) | 2005-01-21 | 2013-04-25 | Merz Pharma Gmbh & Co. Kgaa | Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form |
| CN1930186A (zh) * | 2005-03-03 | 2007-03-14 | 阿勒根公司 | 为获得梭菌毒素的梭菌细菌培养基及方法 |
| DK2154151T3 (da) * | 2005-09-19 | 2011-09-05 | Allergan Inc | Clostridiumtoksinaktiverbare clostridiumtoksiner |
| US20070218084A1 (en) * | 2005-12-30 | 2007-09-20 | Fondazione Pierfranco E Luisa Mariani- Onlus | Method for the Mapping of the Epileptogenic Focus in the Pre-Surgical Evaluation of Patients with Intractable Epilepsy |
| WO2008008805A2 (en) * | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells |
| US8486422B2 (en) * | 2007-07-26 | 2013-07-16 | Allergan, Inc. | Methods of activating clostridial toxins |
| AU2009339292B2 (en) * | 2008-12-10 | 2016-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
| GB0903006D0 (en) * | 2009-02-23 | 2009-04-08 | Syntaxin Ltd | Modified non-cytotoxic proteases |
| WO2010120766A1 (en) * | 2009-04-14 | 2010-10-21 | Mcw Research Foundation, Inc. | Engineered botulinum neurotoxin |
| JP2013514091A (ja) * | 2009-12-16 | 2013-04-25 | アラーガン、インコーポレイテッド | 組込型プロテアーゼ切断部位結合ドメインを含む改変クロストリジウム毒素 |
| WO2012112434A1 (en) | 2011-02-14 | 2012-08-23 | Allergan, Inc. | Inhibiting aberrant blood vessel formation using retargeted endopeptidases |
| GB201219602D0 (en) * | 2012-10-31 | 2012-12-12 | Syntaxin Ltd | Recombinant clostridium botulinum neurotoxins |
| GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| EP3504226A1 (en) * | 2016-08-24 | 2019-07-03 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
-
2012
- 2012-10-31 GB GB201219602A patent/GB201219602D0/en not_active Ceased
-
2013
- 2013-10-31 EA EA201590794A patent/EA201590794A8/ru unknown
- 2013-10-31 PT PT172011983T patent/PT3326644T/pt unknown
- 2013-10-31 PT PT138116058T patent/PT2914282T/pt unknown
- 2013-10-31 SG SG11201502372SA patent/SG11201502372SA/en unknown
- 2013-10-31 HU HUE17201198A patent/HUE048802T2/hu unknown
- 2013-10-31 WO PCT/GB2013/052845 patent/WO2014068317A1/en not_active Ceased
- 2013-10-31 EP EP17201198.3A patent/EP3326644B1/en active Active
- 2013-10-31 KR KR1020207026658A patent/KR102264478B1/ko active Active
- 2013-10-31 IN IN436MUN2015 patent/IN2015MN00436A/en unknown
- 2013-10-31 ES ES13811605.8T patent/ES2662402T3/es active Active
- 2013-10-31 CN CN201380047542.8A patent/CN104755098A/zh active Pending
- 2013-10-31 MX MX2015005156A patent/MX367080B/es active IP Right Grant
- 2013-10-31 DK DK13811605.8T patent/DK2914282T3/en active
- 2013-10-31 BR BR112015005384A patent/BR112015005384A2/pt not_active Application Discontinuation
- 2013-10-31 TW TW107110108A patent/TWI673361B/zh not_active IP Right Cessation
- 2013-10-31 PL PL13811605T patent/PL2914282T3/pl unknown
- 2013-10-31 US US14/427,234 patent/US10030238B2/en active Active
- 2013-10-31 AU AU2013340610A patent/AU2013340610B2/en not_active Ceased
- 2013-10-31 UA UAA201502159A patent/UA118837C2/uk unknown
- 2013-10-31 SG SG10201701140WA patent/SG10201701140WA/en unknown
- 2013-10-31 CA CA2885519A patent/CA2885519A1/en not_active Abandoned
- 2013-10-31 CN CN201910795176.3A patent/CN110499321A/zh active Pending
- 2013-10-31 HU HUE13811605A patent/HUE036764T2/hu unknown
- 2013-10-31 PL PL17201198T patent/PL3326644T3/pl unknown
- 2013-10-31 NZ NZ705575A patent/NZ705575A/en not_active IP Right Cessation
- 2013-10-31 ES ES17201198T patent/ES2788199T3/es active Active
- 2013-10-31 NO NO13811605A patent/NO2914282T3/no unknown
- 2013-10-31 EP EP20153122.5A patent/EP3673914B1/en active Active
- 2013-10-31 AR ARP130103981A patent/AR093309A1/es active IP Right Grant
- 2013-10-31 EP EP13811605.8A patent/EP2914282B1/en active Active
- 2013-10-31 DK DK17201198.3T patent/DK3326644T3/da active
- 2013-10-31 KR KR1020157010099A patent/KR102188539B1/ko active Active
- 2013-10-31 TW TW108125708A patent/TW202012622A/zh unknown
- 2013-10-31 TW TW102139558A patent/TWI626307B/zh not_active IP Right Cessation
-
2015
- 2015-03-03 ZA ZA2015/01449A patent/ZA201501449B/en unknown
- 2015-03-08 IL IL237623A patent/IL237623B/en active IP Right Grant
- 2015-04-23 MX MX2019009222A patent/MX2019009222A/es unknown
-
2018
- 2018-05-21 AU AU2018203556A patent/AU2018203556B2/en not_active Ceased
- 2018-12-10 JP JP2018230980A patent/JP2019068823A/ja not_active Ceased
-
2019
- 2019-12-26 AR ARP190103867A patent/AR117738A2/es unknown
-
2020
- 2020-02-05 JP JP2020017612A patent/JP2020078321A/ja active Pending
- 2020-09-30 AU AU2020244481A patent/AU2020244481A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL237623B (en) | Clostridium botulinum recombinant neurotoxins | |
| ZA201408757B (en) | Engineered botulinum neurotoxin | |
| DK3584317T3 (en) | Clostridium histolyticum enzym | |
| EP2807186A4 (en) | DIFFICULT CLOSTRIDIUM VACCINES COMPRISING RECOMBINANT TOXINS | |
| SG11201607400VA (en) | Manufacture of recombinant clostridium botulinum neurotoxins | |
| IL237132A0 (en) | Variant of the fc region specific to fcгriib | |
| HUE050037T2 (hu) | Liofilizált botulinum toxin készítmény | |
| IL244154A0 (en) | Botulinum neurotoxin for use in the treatment of depression | |
| FR2988733B1 (fr) | Microorganisme recombinant | |
| EP2925362A4 (en) | ANTIBODIES DIRECTED AGAINST CLOSTRIDIUM DIFFICILE | |
| SG11201500980WA (en) | Clostridium difficile polypeptides as vaccine | |
| AP3655A (en) | Improved injections | |
| SG11201404180RA (en) | Cho-gmt recombinant protein expression | |
| HK40023045A (en) | Solid compositions comprising recombinant clostridium botulinum neurotoxins | |
| GB201215440D0 (en) | Improved handover control | |
| GB201210286D0 (en) | Recombinant polypeptide | |
| SG11201504096RA (en) | Recombinant protein |